When Do Tysabri PML Symptoms First Appear?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Guidance to Targeted Risk Management

If you or a loved one is taking Tysabri, recognizing the earliest symptoms of progressive multifocal leukoencephalopathy (PML) can be critical. The medical community has long studied the balance between therapeutic benefit and rare but serious risks, and this page provides a clear timeline of symptom onset, diagnostic steps, and what monitoring involves.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis in adults (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug carries a boxed warning stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by reactivation of the John Cunningham virus (JCV) in the central nervous system, leading to demyelination and progressive neurological decline. Clinical presentation of PML typically includes subacute onset of focal neurological deficits such as hemiparesis, visual field defects, ataxia, and cognitive impairment. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The condition is often fatal, and survivors frequently experience permanent disability. The boxed warning emphasizes that risk factors for PML include the presence of anti-JCV antibodies, longer duration of Tysabri therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefit when initiating or continuing treatment. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 beta-1 integrin on leukocytes, preventing their adhesion to vascular cell adhesion molecule-1 on endothelial cells. This blocks lymphocyte migration across the blood-brain barrier, reducing inflammatory activity in the central nervous system. However, this immunosuppressive effect within the brain impairs immune surveillance against JCV, allowing the virus to replicate unchecked in oligodendrocytes and astrocytes. The resulting lytic infection causes progressive demyelination characteristic of PML. The boxed warning notes that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adverse event data from the FDA Adverse Event Reporting System (FAERS) show that Tysabri is most frequently associated with reports of fatigue, multiple sclerosis relapse, headache, and gait disturbance (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly quantify PML incidence, they underscore the drug's significant side effect profile. The boxed warning also notes that Tysabri increases the risk of herpes encephalitis and meningitis, with serious and sometimes fatal cases reported in the postmarketing setting (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The duration of treatment prior to onset of these infections ranged from a few months to several years.

Legal Implications and Statute of Limitations in Washington

Risk considerations for patients and attorneys in Washington focus on the adequacy of warnings regarding Tysabri and PML. The boxed warning explicitly states that Tysabri increases PML risk and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, particularly for those with anti-JCV antibodies or prior immunosuppressant use. The TOUCH Prescribing Program requires patients to read a Medication Guide and sign an enrollment form acknowledging risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Attorneys evaluating potential claims should examine whether these warnings were effectively communicated and whether any failure to warn contributed to a patient's PML diagnosis. The timeline between Tysabri exposure and documented harm is critical for legal considerations. PML typically develops after prolonged Tysabri use, with risk increasing after two years of treatment. The boxed warning advises monitoring patients for any new sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Washington, the statute of limitations for personal injury claims generally requires filing within three years of the date the injury was discovered or should have been discovered. For PML, this discovery date may be when MRI findings or CSF testing confirm the diagnosis. Attorneys should gather medical records documenting the date of PML diagnosis, Tysabri treatment history, and any prior symptoms that could have prompted earlier detection. Patients affected by Tysabri-associated PML face severe neurological consequences, including permanent disability or death. The boxed warning states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Legal claims may involve allegations that the manufacturer failed to provide adequate warnings about PML risk, particularly for patients with identifiable risk factors. Attorneys should review the patient's anti-JCV antibody status, duration of Tysabri therapy, and history of immunosuppressant use to assess whether the drug's benefits outweighed the known risks. The TOUCH program's enrollment documents may also be relevant to determine what information was provided to the patient. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and a requirement for patient monitoring. The boxed warning and TOUCH program aim to mitigate this risk, but affected patients may still develop PML. Attorneys in Washington must consider the statute of limitations, adequacy of warnings, and timeline of exposure when evaluating potential claims. Medical records, FAERS data, and prescribing information provide the factual basis for these assessments.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington, the statute of limitations for personal injury claims generally requires filing within three years of the date the injury was discovered or should have been discovered. For PML, this discovery date is typically when MRI findings or CSF testing confirm the diagnosis. It is crucial to consult with an attorney promptly to ensure your claim is filed within the applicable timeframe.

What are the key risk factors for developing PML while on Tysabri?

Key risk factors include the presence of anti-JCV antibodies, longer duration of Tysabri therapy (especially beyond two years), and prior use of immunosuppressants. The boxed warning emphasizes these factors should be weighed against expected benefit when initiating or continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.